Nuvalent granted FDA priority review for lung cancer therapy
Nuvalent, Inc. Class A Common Stock · PHARMACEUTICAL PREPARATIONS · Now $93.01
+2.8% in 1d after detection
Post-detection moves
1h
+1.2%
1d
+2.8%
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS